DEPDC1B promotes development of cholangiocarcinoma through enhancing the stability of CDK1 and regulating malignant phenotypes.

Zhang, Zhenhai; Wang, Xinxing; Nie, Peihua; Qin, Yejun; Shi, Junping; Xu, Shifeng

Zhang, Zhenhai; Wang, Xinxing; Nie, Peihua; Qin, Yejun; Shi, Junping; Xu, Shifeng.

Afiliação

Zhang Z; Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Wang X; Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Nie P; Department of Ophthalmology and Otorhinolaryngology, Shandong Provincial Third hospital, Jinan, Shandong, China.
Qin Y; Department of Pathology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
Shi J; Medical Department, OrigiMed, Shanghai, China.
Xu S; Department of Hepatobiliary Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.

Front Oncol ; 12: 842205, 2022.

Article em En | MEDLINE | ID: mdl-36568241

Palavras-chave

CDK1; DEPDC1B; cholangiocarcinoma; tumor promotor; ubiquitination

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Front Oncol Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China País de publicação: Suíça

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google